| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/21/2001 | WO2001043704A1 A skin care composition that mediates cell to cell communication |
| 06/21/2001 | WO2001043697A2 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 06/21/2001 | WO2001043694A2 Compositions and methods for caspase-induced apoptosis |
| 06/21/2001 | WO2001043692A2 SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 06/21/2001 | WO2001043570A1 Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| 06/21/2001 | WO2001026623A3 Treatment of fatigue, head injury and stroke |
| 06/21/2001 | WO2001017955A3 Hydroxyacetamidobenzenesulphonamide derivatives |
| 06/21/2001 | WO2001016136A3 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 06/21/2001 | WO2001014535A3 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc to GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 06/21/2001 | WO2001012787A3 Chimeric dna/rna ribozymes containing propanediol |
| 06/21/2001 | WO2000078972A8 Regulation with binding cassette transporter protein abc1 |
| 06/21/2001 | WO2000075278B1 Gene encoding nade, p75ntr-associated cell death executor and uses thereof |
| 06/21/2001 | WO2000071103A3 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 06/21/2001 | WO2000058472A8 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| 06/21/2001 | WO1998011243A9 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| 06/21/2001 | DE19959546A1 Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen A pharmaceutical preparation for treatment of tumor diseases |
| 06/21/2001 | CA2395585A1 Chimeric natriuretic peptides |
| 06/21/2001 | CA2395486A1 Saccharin derivatives as orally active elastase inhibitors |
| 06/21/2001 | CA2395474A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 06/21/2001 | CA2395088A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 06/21/2001 | CA2395075A1 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
| 06/21/2001 | CA2394570A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 06/21/2001 | CA2394552A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamideinhibitors of cyclin dependent kinases |
| 06/21/2001 | CA2394544A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 06/21/2001 | CA2394538A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 06/21/2001 | CA2394466A1 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | CA2394269A1 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 06/21/2001 | CA2394167A1 Compositions and methods for inhibiting endothelial cell proliferation |
| 06/21/2001 | CA2394160A1 Human oxidoreductase proteins |
| 06/21/2001 | CA2394012A1 Combination of ginseng and ginkgo to improve cognitive skills |
| 06/21/2001 | CA2393972A1 Cyclopenteneone derivatives |
| 06/21/2001 | CA2393808A1 Anti-cancer synthetic oligonucleotides |
| 06/21/2001 | CA2393333A1 Compositions and methods for caspase-induced apoptosis |
| 06/21/2001 | CA2393301A1 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 06/21/2001 | CA2393255A1 Nutritional composition, methods of producing said composition and methods of using said composition |
| 06/21/2001 | CA2393027A1 Inhibitors of interleukin 5 gene expression |
| 06/21/2001 | CA2392944A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors |
| 06/21/2001 | CA2392766A1 Novel helicobacter pylori-binding substances and use thereof |
| 06/21/2001 | CA2391259A1 Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| 06/21/2001 | CA2390821A1 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| 06/21/2001 | CA2390689A1 Human lyases and associated proteins |
| 06/21/2001 | CA2390674A1 Antisense oligonucleotides for the inhibition of expression of type i procollagen |
| 06/21/2001 | CA2390662A1 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 06/21/2001 | CA2383936A1 Novel somatostatin analogs |
| 06/20/2001 | EP1108428A2 Compositions for and uses thereof for treating viral disease with phenylacetate and derivatives thereof |
| 06/20/2001 | EP1108427A2 Compositions for and uses thereof for altering gene expression with phenylacetate and derivatives thereof |
| 06/20/2001 | EP1108424A1 Matrix tablet for sustained release of trimetazidine after oral administration |
| 06/20/2001 | EP1108051A2 Inducible expression system |
| 06/20/2001 | EP1108049A2 Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences |
| 06/20/2001 | EP1108048A1 Cationic complexes of polymer-modified adenovirus |
| 06/20/2001 | EP1108029A1 Kunitz domain polypeptide zkun6 |
| 06/20/2001 | EP1108026A1 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same |
| 06/20/2001 | EP1107989A2 Expression and export of angiostatin and endostatin as immunofusins |
| 06/20/2001 | EP1107986A1 Protein domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 and methods of making and using the same |
| 06/20/2001 | EP1107980A1 CRYSTALLINE FORMS OF EtO 2?C-CH 2?-($i(R))Cgl-Aze-Pab-OH |
| 06/20/2001 | EP1107973A1 Novel compounds |
| 06/20/2001 | EP1107970A2 Collections of compounds |
| 06/20/2001 | EP1107966A2 Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands |
| 06/20/2001 | EP1107965A1 Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application |
| 06/20/2001 | EP1107964A1 Isoquinoline derivatives with angiogenesis inhibiting activity |
| 06/20/2001 | EP1107963A1 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
| 06/20/2001 | EP1107962A1 Quinolin-2-one derivatives useful as anticancer agents |
| 06/20/2001 | EP1107959A2 Quinazoline derivatives as medicaments |
| 06/20/2001 | EP1107957A1 Pyrimidine compounds |
| 06/20/2001 | EP1107954A1 2-OXO-$i(2H)-QUINOLINE DERIVATIVES |
| 06/20/2001 | EP1107953A1 Hydroxamic acid derivatives as proteinase inhibitors |
| 06/20/2001 | EP1107944A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 06/20/2001 | EP1107797A2 Hypoxia regulated genes |
| 06/20/2001 | EP1107794A2 Recombinant botulinium toxin for the treatment of mucus hypersecretion |
| 06/20/2001 | EP1107790A1 Targeting of molecules to large vessel endothelium using epcr |
| 06/20/2001 | EP1107789A1 Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage |
| 06/20/2001 | EP1107780A2 Selective treatment of endothelial somatostatin receptors |
| 06/20/2001 | EP1107777A1 Stabilized pharmaceutical composition in lyophilized form |
| 06/20/2001 | EP1107758A2 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| 06/20/2001 | EP1107757A2 Carbamate and urea compositions and neurotrophic uses |
| 06/20/2001 | EP1107755A1 N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
| 06/20/2001 | EP1107753A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 06/20/2001 | EP1107752A1 Pyrrolidine derivatives for vision and memory disorders |
| 06/20/2001 | EP1107747A1 Therapies for treating pulmonary diseases |
| 06/20/2001 | EP1107746A2 Methods of using and compositions comprising dopamine reuptake inhibitors |
| 06/20/2001 | EP1107745A1 Use of 5ht-6 antagonists |
| 06/20/2001 | EP1107744A2 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 06/20/2001 | EP1107743A1 Stable spray-dried protein formulations |
| 06/20/2001 | EP1107733A1 Oral liquid mucoadhesive compositions |
| 06/20/2001 | EP1107732A1 Oral liquid mucoadhesive compositions |
| 06/20/2001 | EP1107722A2 A method for the treatment of staphylococcal disease |
| 06/20/2001 | EP1107702A1 Ultrasonic enhancement of drug injection |
| 06/20/2001 | EP1071485A4 Revascularization apparatus having coaxial channeling and injection means |
| 06/20/2001 | EP1035780A4 Method for purifying heat shock peptides complexes |
| 06/20/2001 | EP0984961B1 Novel pyridine derivatives and pharmaceutical compositions containing them |
| 06/20/2001 | EP0934301B1 Aminothiophene carboxylic acid amides and the use thereof as phosphodiesterase inhibitors |
| 06/20/2001 | EP0920438B1 N6 heterocyclic substituted adenosine derivatives |
| 06/20/2001 | EP0889875B1 Cyclopropyl alkanoic acid derivatives |
| 06/20/2001 | EP0767658A4 Anti-acne cosmetic compositions |
| 06/20/2001 | EP0757682B1 Benzofuran derivatives useful as inhibitors of bone resorption |
| 06/20/2001 | EP0741732B1 Process for the preparation of a salt of clavulanic acid |
| 06/20/2001 | EP0733043B1 Tricyclic derivatives and their use in pharmaceuticals |
| 06/20/2001 | EP0686037B1 Hormone replacement therapy |
| 06/20/2001 | CN1300323A Recombinant (alpha)-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 06/20/2001 | CN1300303A Enzyme inhibitors |